{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:09:51Z","timestamp":1789013391116,"version":"build-2803163510"},"reference-count":256,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Science and Technology Development Fund of Macau","award":["0065\/2025\/ITP1"],"award-info":[{"award-number":["0065\/2025\/ITP1"]}]},{"name":"the Science and Technology Development Fund of Macau","award":["FDCT\/0150\/2025\/AFJ"],"award-info":[{"award-number":["FDCT\/0150\/2025\/AFJ"]}]},{"name":"the University of Macau","award":["MYRG-GRG2024-00172-FHS"],"award-info":[{"award-number":["MYRG-GRG2024-00172-FHS"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02685-8","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:24:06Z","timestamp":1780298646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection"],"prefix":"10.1186","volume":"25","author":[{"given":"Guanda","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeneng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoufang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"12","key":"2685_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0161-5890(02)00261-4","volume":"39","author":"M Bouvier","year":"2003","unstructured":"Bouvier M. Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective. Mol Immunol. 2003;39(12):697\u2013706.","journal-title":"Mol Immunol"},{"issue":"3","key":"2685_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cell.2005.07.015","volume":"122","author":"KC Garcia","year":"2005","unstructured":"Garcia KC, Adams EJ. How the T cell receptor sees antigen - A structural view. Cell. 2005;122(3):333\u20136.","journal-title":"Cell"},{"key":"2685_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","volume":"24","author":"MG Rudolph","year":"2006","unstructured":"Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol. 2006;24:419\u201366.","journal-title":"Annu Rev Immunol"},{"key":"2685_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev.immunol.18.1.275","volume":"18","author":"JT Harty","year":"2000","unstructured":"Harty JT, Tvinnereim AR, White DW. CD8\u2009+\u2009T cell effector mechanisms in resistance to infection. Annu Rev Immunol. 2000;18:275\u2013308.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"2685_CR5","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1128\/MCB.20.11.3781-3794.2000","volume":"20","author":"M Barry","year":"2000","unstructured":"Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR, et al. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol. 2000;20(11):3781\u201394.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"2685_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.coi.2007.04.011","volume":"19","author":"ME Pipkin","year":"2007","unstructured":"Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol. 2007;19(3):301\u20138.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"2685_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri1032","volume":"3","author":"JA Bluestone","year":"2003","unstructured":"Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3(3):253\u20137.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2685_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nri954","volume":"2","author":"KM Murphy","year":"2002","unstructured":"Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol. 2002;2(12):933\u201344.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2685_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-020-01024-8","volume":"14","author":"J Liu","year":"2021","unstructured":"Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, et al. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021;14(1):21.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2685_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","volume":"229","author":"CE Rudd","year":"2009","unstructured":"Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229(1):12\u201326.","journal-title":"Immunol Rev"},{"issue":"6029","key":"2685_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600\u20133.","journal-title":"Science"},{"issue":"4","key":"2685_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342.","journal-title":"Nat Rev Immunol"},{"key":"2685_CR13","doi-asserted-by":"crossref","unstructured":"Ahmed M, Cheng M, Cheung IY, Cheung NKV. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. Oncoimmunology. 2015;4(4):e989776.","DOI":"10.4161\/2162402X.2014.989776"},{"key":"2685_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","volume":"8","author":"G Fan","year":"2015","unstructured":"Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8:130.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2685_CR15","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927\u201332.","journal-title":"Blood"},{"issue":"10","key":"2685_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1080\/10428194.2025.2525983","volume":"66","author":"K Izutsu","year":"2025","unstructured":"Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, et al. Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. Leuk Lymphoma. 2025;66(10):1913\u201321.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2685_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2685_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","volume":"28","author":"Y Gu","year":"2024","unstructured":"Gu Y, Zhao Q. Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors. Mol Diagn Ther. 2024;28(6):669\u2013702.","journal-title":"Mol Diagn Ther"},{"issue":"Suppl 2","key":"2685_CR19","first-page":"S13","volume":"98","author":"G Ravi","year":"2023","unstructured":"Ravi G, Costa LJ. Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol. 2023;98(Suppl 2):S13\u201321.","journal-title":"Am J Hematol"},{"issue":"10","key":"2685_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","volume":"10","author":"M Herrera","year":"2024","unstructured":"Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM, et al. Bispecific antibodies: advancing precision oncology. Trends Cancer. 2024;10(10):893\u2013919.","journal-title":"Trends Cancer"},{"issue":"7","key":"2685_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0092-8674(02)01194-7","volume":"111","author":"ME Call","year":"2002","unstructured":"Call ME, Pyrdol J, Wiedmann M, Wucherpfennig KW. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell. 2002;111(7):967\u201379.","journal-title":"Cell"},{"key":"2685_CR22","doi-asserted-by":"crossref","unstructured":"Kuhns MS, Davis MM. TCR signaling emerges from the sum of many parts. Front Immunol. 2012;3:159.","DOI":"10.3389\/fimmu.2012.00159"},{"issue":"1","key":"2685_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0092-8674(85)90027-3","volume":"43","author":"LE Samelson","year":"1985","unstructured":"Samelson LE, Harford JB, Klausner RD. Identification of the Components of the Murine T-Cell Antigen Receptor Complex. Cell. 1985;43(1):223\u201331.","journal-title":"Cell"},{"issue":"1","key":"2685_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nri2887","volume":"11","author":"PA van der Merwe","year":"2011","unstructured":"van der Merwe PA, Dushek O. Mechanisms for T cell receptor triggering. Nat Rev Immunol. 2011;11(1):47\u201355.","journal-title":"Nat Rev Immunol"},{"issue":"10396","key":"2685_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402(10396):142\u201358.","journal-title":"Lancet"},{"issue":"6781","key":"2685_CR26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/35010115","volume":"404","author":"JA Gross","year":"2000","unstructured":"Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404(6781):995\u20139.","journal-title":"Nature"},{"issue":"1","key":"2685_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1084\/jem.192.1.129","volume":"192","author":"JS Thompson","year":"2000","unstructured":"Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. 2000;192(1):129\u201335.","journal-title":"J Exp Med"},{"issue":"6","key":"2685_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez E, Li MJ, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Brit J Haematol. 2012;158(6):727\u201338.","journal-title":"Brit J Haematol"},{"issue":"18","key":"2685_CR29","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"18","key":"2685_CR30","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li YZ, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4(18):4538\u201349.","journal-title":"Blood Adv"},{"issue":"10301","key":"2685_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"key":"2685_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, Nooka AK, van de Donk NWCJ, Moreau P, Bhutani M, Oriol A, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:16.","journal-title":"J Clin Oncol"},{"key":"2685_CR33","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.jbior.2025.101116","volume":"99","author":"S Schurmans","year":"2026","unstructured":"Schurmans S, Moes B. CD19 structure, expression, and signaling: From basic mechanisms to therapeutic targeting. Adv Biol Regul. 2026;99:101116.","journal-title":"Adv Biol Regul"},{"key":"2685_CR34","doi-asserted-by":"publisher","first-page":"837457","DOI":"10.3389\/fimmu.2022.837457","volume":"13","author":"M Gambella","year":"2022","unstructured":"Gambella M, Carlomagno S, Raiola AM, Giannoni L, Ghiggi C, Setti C, et al. CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma. Front Immunol. 2022;13:837457.","journal-title":"Front Immunol"},{"issue":"6","key":"2685_CR35","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ijc.10557","volume":"100","author":"T Dreier","year":"2002","unstructured":"Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002;100(6):690\u20137.","journal-title":"Int J Cancer"},{"issue":"1","key":"2685_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115(1):98\u2013104.","journal-title":"Int J Cancer"},{"issue":"36","key":"2685_CR37","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134\u201340.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2685_CR38","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an enigma of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506.","journal-title":"Haematologica"},{"issue":"2","key":"2685_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","volume":"11","author":"HJ van der Horst","year":"2021","unstructured":"van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry D, Hijmering NJ, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021;11(2):38.","journal-title":"Blood Cancer J"},{"issue":"3","key":"2685_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00277-026-06798-4","volume":"105","author":"YH Karimi","year":"2026","unstructured":"Karimi YH, Cheah CY, Clausen MR, Cunningham D, Farooq U, Feldman T, et al. Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial. Ann Hematol. 2026;105(3):79.","journal-title":"Ann Hematol"},{"key":"2685_CR41","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K et al. vol 14, 24,. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review (2024). Blood Cancer Journal. 2024;14(1).","DOI":"10.1038\/s41408-023-00966-9"},{"issue":"6","key":"2685_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/jb\/mvaa030","volume":"167","author":"Y Hirabayashi","year":"2020","unstructured":"Hirabayashi Y, Kim YJ. Roles of GPRC5 family proteins: focusing on GPRC5B and lipid-mediated signalling. J Biochem. 2020;167(6):541\u20137.","journal-title":"J Biochem"},{"issue":"8","key":"2685_CR43","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196\u2013215.","journal-title":"Blood Adv"},{"issue":"4","key":"2685_CR44","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3324\/haematol.2025.287334","volume":"111","author":"G An","year":"2026","unstructured":"An G, Jin J, Cai Z, Jing H, Fu C, He P, et al. Talquetamab, a GPRC5DxCD3 bispecific antibody, in Chinese patients with relapsed\/refractory multiple myeloma: efficacy and safety from the phase 1\/2 MonumenTAL-1 study. Haematologica. 2026;111(4):1411\u20136.","journal-title":"Haematologica"},{"issue":"4","key":"2685_CR45","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol. 2025;12(4):e269\u201381.","journal-title":"Lancet Haematol"},{"issue":"1","key":"2685_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0925-4773(00)00514-1","volume":"100","author":"K Kusumi","year":"2001","unstructured":"Kusumi K, Dunwoodie SL, Krumlauf R. Dynamic expression patterns of the pudgy\/spondylocostal dysostosis gene Dll3 in the developing nervous system. Mech Dev. 2001;100(1):141\u20134.","journal-title":"Mech Dev"},{"issue":"5","key":"2685_CR47","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/hmg\/ddq529","volume":"20","author":"G Chapman","year":"2011","unstructured":"Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet. 2011;20(5):905\u201316.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2685_CR48","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1083\/jcb.200702009","volume":"178","author":"I Geffers","year":"2007","unstructured":"Geffers I, Serth K, Chapman G, Jaekel R, Schuster-Gossler K, Cordes R, et al. Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo. J Cell Biol. 2007;178(3):465\u201376.","journal-title":"J Cell Biol"},{"issue":"23","key":"2685_CR49","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1242\/dev.083840","volume":"139","author":"M Morimoto","year":"2012","unstructured":"Morimoto M, Nishinakamura R, Saga Y, Kopan R. Different assemblies of Notch receptors coordinate the distribution of the major bronchial Clara, ciliated and neuroendocrine cells. Development. 2012;139(23):4365\u201373.","journal-title":"Development"},{"issue":"1","key":"2685_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","volume":"12","author":"DH Owen","year":"2019","unstructured":"Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12(1):61.","journal-title":"J Hematol Oncol"},{"issue":"302","key":"2685_CR51","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2685_CR52","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","volume":"27","author":"MJ Giffin","year":"2021","unstructured":"Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021;27(5):1526\u201337.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2685_CR53","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023;41(16):2893\u2013903.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2685_CR54","first-page":"227","volume":"20","author":"NM Hawkey","year":"2022","unstructured":"Hawkey NM, Sartor AO, Morris MJ, Armstrong AJ. Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. Clin Adv Hematol Oncol. 2022;20(4):227\u201338.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"2685_CR55","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","volume":"27","author":"P Deegen","year":"2021","unstructured":"Deegen P, Thomas O, Nolan-Stevaux O, Li S, Wahl J, Bogner P, et al. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021;27(10):2928\u201337.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2685_CR56","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, et al. A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024;30(8):1488\u2013500.","journal-title":"Clin Cancer Res"},{"key":"2685_CR57","doi-asserted-by":"crossref","unstructured":"Muth A, Holzem A, Neumann AS, Buecklein VL, Subklewe M, Philipp N. T cell exhaustion in bi- and trispecific T cell engager therapy in hematologic malignancies: Mechanisms and implications. Med. 2026:101031.","DOI":"10.1016\/j.medj.2026.101031"},{"issue":"2","key":"2685_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41577-025-01221-x","volume":"26","author":"Q Sun","year":"2026","unstructured":"Sun Q, Dong C. Regulators of CD8(+) T cell exhaustion. Nat Rev Immunol. 2026;26(2):129\u201351.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2685_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41392-025-02327-3","volume":"11","author":"Y Wu","year":"2026","unstructured":"Wu Y, Wu Y, Gao Z, Yu W, Zhang L, Zhou F. Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion. Signal Transduct Target Ther. 2026;11(1):2.","journal-title":"Signal Transduct Target Ther"},{"key":"2685_CR60","doi-asserted-by":"crossref","unstructured":"Wu H, Zhao XF, Hochrein SM, Eckstein M, Gubert GF, Kn\u00f6pper K et al. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming. Nat Commun. 2023;14(1):6858.","DOI":"10.1038\/s41467-023-42634-3"},{"issue":"2","key":"2685_CR61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping NE, Rivadeneira DB, Menk A, Vignali PDA, Ford BR, Rittenhouse NL, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22(2):205\u2013U190.","journal-title":"Nat Immunol"},{"issue":"1","key":"2685_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1158\/0008-5472.CAN-25-4716","volume":"86","author":"T Mitra","year":"2026","unstructured":"Mitra T, Vardhana SA. Between ROS and a Hard Place: Telomere Damage as a Driver of T-cell Exhaustion. Cancer Res. 2026;86(1):10\u20131.","journal-title":"Cancer Res"},{"issue":"1","key":"2685_CR63","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.trecan.2025.09.004","volume":"12","author":"JQ Wang","year":"2026","unstructured":"Wang JQ, Yan RC, Jia DJC, Chen SJ. Reprogramming T cell stemness against cancer. Trends Cancer. 2026;12(1):68\u201379.","journal-title":"Trends Cancer"},{"key":"2685_CR64","doi-asserted-by":"crossref","unstructured":"Yang AR, Zhou M, Gao YX, Zhang Y. Mechanisms of CD8\u2009+\u2009T cell exhaustion and its clinical significance in prognosis of anti-tumor therapies: A review. Int Immunopharmacol. 2025;159:114843.","DOI":"10.1016\/j.intimp.2025.114843"},{"key":"2685_CR65","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1182\/blood-2024-211459","volume":"144","author":"G Magno","year":"2024","unstructured":"Magno G, Rejeski K, Rappa G, Kupf S, Stock S, Holzem AME, et al. Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R\/R LBCL. Blood. 2024;144:1714\u20135.","journal-title":"Blood"},{"key":"2685_CR66","doi-asserted-by":"crossref","unstructured":"Chong EA, Penuel E, Bartlett NL, Bosch F, Budde LE, Fay K et al. Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts. Blood. 2023;142 (Supplement 1):1752.","DOI":"10.1182\/blood-2023-190201"},{"issue":"1","key":"2685_CR67","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12957-022-02810-z","volume":"20","author":"B Mollavelioglu","year":"2022","unstructured":"Mollavelioglu B, Cetin Aktas E, Cabioglu N, Abbasov A, Onder S, Emiroglu S, et al. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. World J Surg Oncol. 2022;20(1):349.","journal-title":"World J Surg Oncol"},{"issue":"5","key":"2685_CR68","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/2159-8290.CD-21-0257","volume":"11","author":"EM Burton","year":"2021","unstructured":"Burton EM, Tawbi HA. Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021;11(5):1008\u201310.","journal-title":"Cancer Discov"},{"key":"2685_CR69","doi-asserted-by":"crossref","unstructured":"Ma Y, Xue J, Zhao Y, Zhang Y, Huang Y, Yang Y et al. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. J Immunother Cancer. 2023;11(6):e006654.","DOI":"10.1136\/jitc-2022-006654"},{"issue":"12","key":"2685_CR70","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/1947601911432334","volume":"2","author":"S Ziyad","year":"2011","unstructured":"Ziyad S, Iruela-Arispe ML. Molecular mechanisms of tumor angiogenesis. Genes Cancer. 2011;2(12):1085\u201396.","journal-title":"Genes Cancer"},{"key":"2685_CR71","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev.med.49.1.407","volume":"49","author":"BR Zetter","year":"1998","unstructured":"Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407\u201324.","journal-title":"Annu Rev Med"},{"issue":"Suppl 1","key":"2685_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.5-suppl_1-3","volume":"5","author":"G McMahon","year":"2000","unstructured":"McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5(Suppl 1):3\u201310.","journal-title":"Oncologist"},{"issue":"3","key":"2685_CR73","doi-asserted-by":"publisher","first-page":"111722","DOI":"10.1016\/j.isci.2024.111722","volume":"28","author":"T Zhong","year":"2025","unstructured":"Zhong T, Zhang L, Huang Z, Pang X, Jin C, Liu W, et al. Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects. iScience. 2025;28(3):111722.","journal-title":"iScience"},{"issue":"3","key":"2685_CR74","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","volume":"19","author":"L Wang","year":"2024","unstructured":"Wang L, Luo Y, Ren S, Zhang Z, Xiong A, Su C, et al. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. J Thorac Oncol. 2024;19(3):465\u201375.","journal-title":"J Thorac Oncol"},{"key":"2685_CR75","doi-asserted-by":"publisher","first-page":"1499663","DOI":"10.3389\/fimmu.2025.1499663","volume":"16","author":"R Liu","year":"2025","unstructured":"Liu R, Jiang X, Dong R, Zhang Y, Gai C, Wei P. Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families. Front Immunol. 2025;16:1499663.","journal-title":"Front Immunol"},{"key":"2685_CR76","doi-asserted-by":"crossref","unstructured":"Dadfar S, Eivazzadeh Y, Molavi H, Abedi H, Tavassoli Razavi F, Haghmorad D. Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy. Inflamm Res. 2026;75(1):58.","DOI":"10.1007\/s00011-026-02211-y"},{"issue":"4","key":"2685_CR77","doi-asserted-by":"publisher","first-page":"e70196","DOI":"10.1002\/iid3.70196","volume":"13","author":"E Rezazadeh-Gavgani","year":"2025","unstructured":"Rezazadeh-Gavgani E, Majidazar R, Lotfinejad P, Kazemi T, Shamekh A. Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications. Immun Inflamm Dis. 2025;13(4):e70196.","journal-title":"Immun Inflamm Dis"},{"key":"2685_CR78","doi-asserted-by":"publisher","first-page":"155864","DOI":"10.1016\/j.prp.2025.155864","volume":"269","author":"D Aden","year":"2025","unstructured":"Aden D, Zaheer S, Sureka N, Trisal M, Chaurasia JK, Zaheer S. Exploring immune checkpoint inhibitors: Focus on PD-1\/PD-L1 axis and beyond. Pathol Res Pract. 2025;269:155864.","journal-title":"Pathol Res Pract"},{"key":"2685_CR79","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"M Tekguc","year":"2021","unstructured":"Tekguc M, Wing JB, Osaki M, Long J, Sakaguchi S. Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci U S A. 2021;118:30.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2685_CR80","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","volume":"36","author":"LS Walker","year":"2015","unstructured":"Walker LS, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 2015;36(2):63\u201370.","journal-title":"Trends Immunol"},{"key":"2685_CR81","first-page":"310","volume":"25","author":"OO Khan","year":"2026","unstructured":"Khan OO. Efficacy and Safety of Ctla-4, Pd-1 and Lag-3 Immune Checkpoint Inhibitors as Monotherapy and Combination Therapy in Advanced Melanoma: A Systematic Review and Meta-Analysis. Excli J. 2026;25:310\u201329.","journal-title":"Excli J"},{"key":"2685_CR82","doi-asserted-by":"publisher","first-page":"1688699","DOI":"10.3389\/fimmu.2025.1688699","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, He J, Ding G, Tang Y, Wang Q. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol. 2025;16:1688699.","journal-title":"Front Immunol"},{"key":"2685_CR83","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.ctrv.2023.102614","volume":"120","author":"M Borgeaud","year":"2023","unstructured":"Borgeaud M, Sandoval J, Obeid M, Banna G, Michielin O, Addeo A, et al. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat Rev. 2023;120:102614.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2685_CR84","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","volume":"6","author":"RY Huang","year":"2017","unstructured":"Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6(1):e1249561.","journal-title":"Oncoimmunology"},{"key":"2685_CR85","doi-asserted-by":"crossref","unstructured":"Shentu J, Xu H, Duan S. Synergistic PD-1\/LAG-3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy. MedComm (2020). 2025;6(6):e70216.","DOI":"10.1002\/mco2.70216"},{"key":"2685_CR86","doi-asserted-by":"crossref","unstructured":"Xiang SM, Li S, Xu JF. Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy. Clin Transl Med. 2025;15(5):e70345.","DOI":"10.1002\/ctm2.70345"},{"issue":"5","key":"2685_CR87","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","volume":"11","author":"SJ Dovedi","year":"2021","unstructured":"Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, et al. Design and Efficacy of a Monovalent Bispecific PD-1\/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1(+) Activated T Cells. Cancer Discov. 2021;11(5):1100\u201317.","journal-title":"Cancer Discov"},{"issue":"1","key":"2685_CR88","doi-asserted-by":"publisher","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","volume":"15","author":"X Pang","year":"2023","unstructured":"Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, et al. Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs. 2023;15(1):2180794.","journal-title":"MAbs"},{"key":"2685_CR89","doi-asserted-by":"publisher","first-page":"1264327","DOI":"10.3389\/fimmu.2023.1264327","volume":"14","author":"D Roy","year":"2023","unstructured":"Roy D, Gilmour C, Patnaik S, Wang LL. Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors. Front Immunol. 2023;14:1264327.","journal-title":"Front Immunol"},{"issue":"10","key":"2685_CR90","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 2023;24(10):1134\u201346.","journal-title":"Lancet Oncol"},{"issue":"45","key":"2685_CR91","doi-asserted-by":"publisher","first-page":"22699","DOI":"10.1073\/pnas.1821218116","volume":"116","author":"SC Wei","year":"2019","unstructured":"Wei SC, Anang NAAS, Sharma R, Andrews MC, Reuben A, Levine JH, et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. P Natl Acad Sci USA. 2019;116(45):22699\u2013709.","journal-title":"P Natl Acad Sci USA"},{"key":"2685_CR92","doi-asserted-by":"crossref","unstructured":"Crosby EJ, Wei JPP, Yang XY, Lei GJ, Wang T, Liu CX et al. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology. 2018;7(5):e1421891.","DOI":"10.1080\/2162402X.2017.1421891"},{"issue":"1","key":"2685_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"2","key":"2685_CR94","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127\u2013.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2685_CR95","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New Engl J Med. 2022;386(5):449\u201362.","journal-title":"New Engl J Med"},{"issue":"14","key":"2685_CR96","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New Engl J Med. 2018;378(14):1277\u201390.","journal-title":"New Engl J Med"},{"issue":"2","key":"2685_CR97","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198\u2013211.","journal-title":"Lancet Oncol"},{"issue":"16","key":"2685_CR98","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1016\/j.cell.2024.07.018","volume":"187","author":"SF Ngiow","year":"2024","unstructured":"Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Mathew D, et al. LAG-3 sustains TOX expression and regulates the CD94\/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell. 2024;187(16):4336\u2013e5419.","journal-title":"Cell"},{"issue":"1","key":"2685_CR99","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-024-02000-1","volume":"9","author":"M Hofmann","year":"2024","unstructured":"Hofmann M, Thimme R, Schamel WW. PD-1 and LAG-3: synergistic fostering of T cell exhaustion. Signal Transduct Target Ther. 2024;9(1):291.","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"2685_CR100","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","volume":"28","author":"LP Andrews","year":"2022","unstructured":"Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022;28(23):5030\u20139.","journal-title":"Clin Cancer Res"},{"issue":"29","key":"2685_CR101","doi-asserted-by":"publisher","first-page":"27359","DOI":"10.18632\/oncotarget.4751","volume":"6","author":"RY Huang","year":"2015","unstructured":"Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8\u2009+\u2009T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6(29):27359\u201377.","journal-title":"Oncotarget"},{"key":"2685_CR102","doi-asserted-by":"crossref","unstructured":"Lipson EJ, Tawbi HAH, Schadendorf D, Ascierto PA, Matamala L, Guti\u00e9rrez EC et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol. 2021;39(15):15_suppl.","DOI":"10.1200\/JCO.2021.39.15_suppl.9503"},{"key":"2685_CR103","doi-asserted-by":"publisher","first-page":"100079","DOI":"10.1016\/j.iotech.2022.100079","volume":"14","author":"L Chocarro","year":"2022","unstructured":"Chocarro L, Blanco E, Arasanz H, Fernandez-Rubio L, Bocanegra A, Echaide M, et al. Clinical landscape of LAG-3-targeted therapy. Immunooncol Technol. 2022;14:100079.","journal-title":"Immunooncol Technol"},{"issue":"6","key":"2685_CR104","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.esmoop.2022.100639","volume":"7","author":"E Garralda","year":"2022","unstructured":"Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, et al. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022;7(6):100639.","journal-title":"ESMO Open"},{"issue":"12","key":"2685_CR105","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s43018-024-00870-6","volume":"5","author":"K Nutsch","year":"2024","unstructured":"Nutsch K, Banta KL, Wu TD, Tran CW, Mittman S, Duong E, et al. TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation. Nat Cancer. 2024;5(12):1834\u201351.","journal-title":"Nat Cancer"},{"issue":"3","key":"2685_CR106","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O\u2019Gorman WE, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity. 2022;55(3):512\u201326. e9.","journal-title":"Immunity"},{"issue":"2","key":"2685_CR107","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jcmgh.2021.03.003","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge Z, Zhou G, Campos Carrascosa L, Gausvik E, Boor PPC, Noordam L, et al. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8(+) T Cells in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2021;12(2):443\u201364.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"2685_CR108","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781\u201392.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2685_CR109","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12(1):832.","journal-title":"Nat Commun"},{"issue":"5","key":"2685_CR110","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1158\/0008-5472.CAN-16-0274","volume":"77","author":"C Granier","year":"2017","unstructured":"Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, et al. Tim-3 Expression on Tumor-Infiltrating PD-1(+)CD8(+) T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. Cancer Res. 2017;77(5):1075\u201382.","journal-title":"Cancer Res"},{"issue":"4","key":"2685_CR111","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/CJI.0000000000000122","volume":"39","author":"J Liu","year":"2016","unstructured":"Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, et al. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic\/Tumor Vaccines. J Immunother. 2016;39(4):171\u201380.","journal-title":"J Immunother"},{"key":"2685_CR112","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1200\/JCO.2023.41.4_suppl.580","volume":"41","author":"JD Acoba","year":"2023","unstructured":"Acoba JD, Rho Y, Fukaya E. Phase II study of cobolimab in combination with dostarlimab for the treatment of advanced hepatocellular carcinoma. J Clin Oncol. 2023;41:580.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2685_CR113","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","volume":"27","author":"G Curigliano","year":"2021","unstructured":"Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, et al. Phase I\/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2021;27(13):3620\u20139.","journal-title":"Clin Cancer Res"},{"key":"2685_CR114","doi-asserted-by":"crossref","unstructured":"Falchook GS, Ribas A, Davar D, Eroglu Z, Wang JS, Luke JJ et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER). J Clin Oncol. 2022;40(16):16_suppl.","DOI":"10.1200\/JCO.2022.40.16_suppl.2504"},{"key":"2685_CR115","doi-asserted-by":"publisher","first-page":"968360","DOI":"10.3389\/fonc.2022.968360","volume":"12","author":"AMJ Kim","year":"2022","unstructured":"Kim AMJ, Nemeth MR, Lim SO. 4-1BB: A promising target for cancer immunotherapy. Front Oncol. 2022;12:968360.","journal-title":"Front Oncol"},{"issue":"12","key":"2685_CR116","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41577-024-01061-1","volume":"24","author":"MT Lotze","year":"2024","unstructured":"Lotze MT, Olejniczak SH, Skokos D. CD28 co-stimulation: novel insights and applications in cancer immunotherapy. Nat Rev Immunol. 2024;24(12):878\u201395.","journal-title":"Nat Rev Immunol"},{"key":"2685_CR117","doi-asserted-by":"publisher","first-page":"1674818","DOI":"10.3389\/fimmu.2025.1674818","volume":"16","author":"M Zhang","year":"2025","unstructured":"Zhang M, Xu J, Zheng Z, Guo Z, Wang H, Zhou M, et al. The role of immune checkpoint molecules in cancers. Front Immunol. 2025;16:1674818.","journal-title":"Front Immunol"},{"issue":"1","key":"2685_CR118","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","volume":"20","author":"Q Ye","year":"2014","unstructured":"Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20(1):44\u201355.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2685_CR119","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1084\/jem.186.1.47","volume":"186","author":"WW Shuford","year":"1997","unstructured":"Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, et al. 4-1BB costimulatory signals preferentially induce CD8\u2009+\u2009T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186(1):47\u201355.","journal-title":"J Exp Med"},{"issue":"5","key":"2685_CR120","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","volume":"12","author":"A Muik","year":"2022","unstructured":"Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, et al. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022;12(5):1248\u201365.","journal-title":"Cancer Discov"},{"key":"2685_CR121","unstructured":"Aerts J. Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial. https:\/\/www.asco.org\/abstracts-presentations\/233961\/abstract. Accessed 31 March 2026."},{"issue":"15","key":"2685_CR122","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.2174\/1389201017666161018150553","volume":"17","author":"Z Chen","year":"2016","unstructured":"Chen Z, Wang L, Xu T, Wang Q, Kang L, Zhao Q. Generation of Bispecific Antibodies by Fc Heterodimerization and their Application. Curr Pharm Biotechnol. 2016;17(15):1324\u201332.","journal-title":"Curr Pharm Biotechnol"},{"issue":"3","key":"2685_CR123","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.yexmp.2014.09.007","volume":"97","author":"Y Feng","year":"2014","unstructured":"Feng Y, Zhao Q, Chen W, Wang Y, Crowder K, Dimitrov DS. A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques. Exp Mol Pathol. 2014;97(3):359\u201367.","journal-title":"Exp Mol Pathol"},{"key":"2685_CR124","doi-asserted-by":"publisher","first-page":"1304365","DOI":"10.3389\/fimmu.2023.1304365","volume":"14","author":"T Damelang","year":"2023","unstructured":"Damelang T, Brinkhaus M, van Osch TLJ, Schuurman J, Labrijn AF, Rispens T, et al. Impact of structural modifications of IgG antibodies on effector functions. Front Immunol. 2023;14:1304365.","journal-title":"Front Immunol"},{"key":"2685_CR125","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"issue":"12","key":"2685_CR126","doi-asserted-by":"publisher","first-page":"e1008064","DOI":"10.1371\/journal.ppat.1008064","volume":"15","author":"SI Richardson","year":"2019","unstructured":"Richardson SI, Lambson BE, Crowley AR, Bashirova A, Scheepers C, Garrett N, et al. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathog. 2019;15(12):e1008064.","journal-title":"PLoS Pathog"},{"issue":"8","key":"2685_CR127","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41590-023-01544-8","volume":"24","author":"F Nimmerjahn","year":"2023","unstructured":"Nimmerjahn F, Vidarsson G, Cragg MS. Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy. Nat Immunol. 2023;24(8):1244\u201355.","journal-title":"Nat Immunol"},{"issue":"11","key":"2685_CR128","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","volume":"23","author":"T Rispens","year":"2023","unstructured":"Rispens T, Huijbers MG. The unique properties of IgG4 and its roles in health and disease. Nat Rev Immunol. 2023;23(11):763\u201378.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2685_CR129","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0022-1759(94)90108-2","volume":"172","author":"R Bazin","year":"1994","unstructured":"Bazin R, Boucher G, Monier G, Chevrier MC, Verrette S, Broly H, et al. Use of hu-IgG-SCID mice to evaluate the in vivo stability of human monoclonal IgG antibodies. J Immunol Methods. 1994;172(2):209\u201317.","journal-title":"J Immunol Methods"},{"issue":"5","key":"2685_CR130","doi-asserted-by":"publisher","first-page":"e0177736","DOI":"10.1371\/journal.pone.0177736","volume":"12","author":"R Braster","year":"2017","unstructured":"Braster R, Grewal S, Visser R, Einarsdottir HK, van Egmond M, Vidarsson G, et al. Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice. PLoS ONE. 2017;12(5):e0177736.","journal-title":"PLoS ONE"},{"issue":"6","key":"2685_CR131","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1080\/19420862.2019.1624464","volume":"11","author":"S Kapelski","year":"2019","unstructured":"Kapelski S, Cleiren E, Attar RM, Philippar U, Hasler J, Chiu ML. Influence of the bispecific antibody IgG subclass on T cell redirection. MAbs. 2019;11(6):1012\u201324.","journal-title":"MAbs"},{"issue":"1","key":"2685_CR132","doi-asserted-by":"publisher","first-page":"1829338","DOI":"10.1080\/19420862.2020.1829338","volume":"12","author":"Z Chen","year":"2020","unstructured":"Chen Z, Qian Y, Song Y, Xu X, Tao L, Mussa N, et al. Design of next-generation therapeutic IgG4 with improved manufacturability and bioanalytical characteristics. MAbs. 2020;12(1):1829338.","journal-title":"MAbs"},{"issue":"1","key":"2685_CR133","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"J Yu","year":"2020","unstructured":"Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13(1):45.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2685_CR134","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"2685_CR135","doi-asserted-by":"crossref","unstructured":"Kuwahara A, Nagai K, Nakanishi T, Kumagai I, Asano R. Functional Domain Order of an Anti-EGFR x Anti-CD16 Bispecific Diabody Involving NK Cell Activation. Int J Mol Sci. 2020;21(23):8914.","DOI":"10.3390\/ijms21238914"},{"issue":"1","key":"2685_CR136","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.4110\/in.2022.22.e4","volume":"22","author":"D Moon","year":"2022","unstructured":"Moon D, Tae N, Park Y, Lee SW, Kim DH. Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody. Immune Netw. 2022;22(1):e4.","journal-title":"Immune Netw"},{"issue":"22","key":"2685_CR137","doi-asserted-by":"publisher","first-page":"e2425781122","DOI":"10.1073\/pnas.2425781122","volume":"122","author":"A Leithner","year":"2025","unstructured":"Leithner A, Staufer O, Mitra T, Liberta F, Valvo S, Kutuzov M, et al. Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency. Proc Natl Acad Sci U S A. 2025;122(22):e2425781122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2685_CR138","first-page":"995","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S, Tarlatamab. First Approval Drugs. 2024;84(8):995\u20131003.","journal-title":"First Approval Drugs"},{"issue":"9","key":"2685_CR139","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/1535-7163.MCT-23-0524","volume":"23","author":"ME Molloy","year":"2024","unstructured":"Molloy ME, Aaron WH, Barath M, Bush MC, Callihan EC, Carlin K, et al. HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors. Mol Cancer Ther. 2024;23(9):1294\u2013304.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2685_CR140","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12032-025-03232-z","volume":"43","author":"S Chen","year":"2026","unstructured":"Chen S, Zhang G, He X, Li Y, Li D. Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy. Med Oncol. 2026;43(3):145.","journal-title":"Med Oncol"},{"key":"2685_CR141","unstructured":"Paz-Ares LG. ea. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.TPS8611. Accessed 7 April 2026."},{"key":"2685_CR142","doi-asserted-by":"publisher","unstructured":"Beltran H. April ea. Updated results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8090. Accessed 7 2026.","DOI":"10.1200\/JCO.2024.42.16_suppl.8090"},{"issue":"1","key":"2685_CR143","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-012-0008-z","volume":"27","author":"P Fournier","year":"2013","unstructured":"Fournier P, Schirrmacher V. Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer Preparing for the Future. Biodrugs. 2013;27(1):35\u201353.","journal-title":"Biodrugs"},{"issue":"2","key":"2685_CR144","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/ijc.29007","volume":"136","author":"M Cheng","year":"2015","unstructured":"Cheng M, Ahmed M, Xu H, Cheung NKV. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer. 2015;136(2):476\u201386.","journal-title":"Int J Cancer"},{"key":"2685_CR145","doi-asserted-by":"crossref","unstructured":"Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T et al. Design and Production of Bispecific Antibodies. Antibodies (Basel). 2019;8(3):43.","DOI":"10.3390\/antib8030043"},{"issue":"5","key":"2685_CR146","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","volume":"17","author":"H Li","year":"2020","unstructured":"Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol. 2020;17(5):451\u201361.","journal-title":"Cell Mol Immunol"},{"key":"2685_CR147","doi-asserted-by":"crossref","unstructured":"Fawcett C, Tickle JR, Coles CH. Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows. Mabs. 2024;16(1):2311992.","DOI":"10.1080\/19420862.2024.2311992"},{"key":"2685_CR148","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-cancerbio-070620-104325","volume":"6","author":"T Arvedson","year":"2022","unstructured":"Arvedson T, Bailis JM, Britten CD, Klinger M, Nagorsen D, Coxon A, et al. Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. Annu Rev Cancer Biol. 2022;6:17\u201334.","journal-title":"Annu Rev Cancer Biol"},{"issue":"5","key":"2685_CR149","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","volume":"34","author":"PA Baeuerle","year":"2022","unstructured":"Baeuerle PA, Wesche H. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Curr Opin Oncol. 2022;34(5):552\u20138.","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"2685_CR150","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"2685_CR151","doi-asserted-by":"crossref","unstructured":"Liu JJ, Zhu JW. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors. Int Immunopharmacol. 2024;138:112609.","DOI":"10.1016\/j.intimp.2024.112609"},{"issue":"2","key":"2685_CR152","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2685_CR153","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","volume":"30","author":"N Frey","year":"2017","unstructured":"Frey N. Cytokine release syndrome: Who is at risk and how to treat. Best Pract Res Cl Ha. 2017;30(4):336\u201340.","journal-title":"Best Pract Res Cl Ha"},{"key":"2685_CR154","doi-asserted-by":"crossref","unstructured":"Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavar\u00e9 R et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep-Uk. 2021;11(1):14397.","DOI":"10.1038\/s41598-021-93842-0"},{"issue":"4","key":"2685_CR155","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","volume":"11","author":"ND Trinklein","year":"2019","unstructured":"Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. Mabs. 2019;11(4):639\u201352.","journal-title":"Mabs"},{"key":"2685_CR156","doi-asserted-by":"crossref","unstructured":"Dang K, Castello G, Clarke SC, Li YP, Balasubramani A, Boudreau A et al. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. J Immunother Cancer. 2021;9(6):e002488.","DOI":"10.1136\/jitc-2021-002488"},{"key":"2685_CR157","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2024.42.16_suppl.e14587","volume":"42","author":"GS Falchook","year":"2024","unstructured":"Falchook GS, McKean M, Kelly WK, Patel MR, Bupathi M, Liaw BCH, et al. Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42:16.","journal-title":"J Clin Oncol"},{"key":"2685_CR158","doi-asserted-by":"publisher","first-page":"102189","DOI":"10.1016\/j.ctrv.2021.102189","volume":"97","author":"P Roth","year":"2021","unstructured":"Roth P, Winklhofer S, Muller AMS, Dummer R, Mair MJ, Gramatzki D, et al. Neurological complications of cancer immunotherapy. Cancer Treat Rev. 2021;97:102189.","journal-title":"Cancer Treat Rev"},{"key":"2685_CR159","doi-asserted-by":"crossref","unstructured":"Burke KP, Grebinoski S, Sharpe AH, Vignali DAA. Understanding adverse events of immunotherapy: A mechanistic perspective. J Exp Med. 2021;218(1):e20192179.","DOI":"10.1084\/jem.20192179"},{"issue":"1","key":"2685_CR160","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/0008-5472.CAN-19-1131","volume":"80","author":"M Klinger","year":"2020","unstructured":"Klinger M, Zugmaier G, Nagele V, Goebeler ME, Brandl C, Stelljes M, et al. Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events. Cancer Res. 2020;80(1):91\u2013101.","journal-title":"Cancer Res"},{"issue":"1","key":"2685_CR161","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","volume":"98","author":"AS Stein","year":"2019","unstructured":"Stein AS, Schiller G, Benjamin R, Jia C, Zhang A, Zhu M, et al. Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98(1):159\u201367.","journal-title":"Ann Hematol"},{"key":"2685_CR162","doi-asserted-by":"crossref","unstructured":"Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y et al. An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. 2017;9(410):eaal4291.","DOI":"10.1126\/scitranslmed.aal4291"},{"key":"2685_CR163","doi-asserted-by":"crossref","unstructured":"Kauer J, Horner S, Osburg L, Muller S, Marklin M, Heitmann JS et al. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer. 2020;8(1):e000621.","DOI":"10.1136\/jitc-2020-000621"},{"issue":"2","key":"2685_CR164","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","volume":"31","author":"KK Radtke","year":"2025","unstructured":"Radtke KK, Bender BC, Li Z, Turner DC, Roy S, Belousov A, et al. Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies. Clin Cancer Res. 2025;31(2):245\u201357.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2685_CR165","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/cncr.30579","volume":"123","author":"AR Hansen","year":"2017","unstructured":"Hansen AR, Cook N, Amir E, Siu LL, Razak ARA. Determinants of the recommended phase 2 dose of molecular targeted agents. Cancer. 2017;123(8):1409\u201315.","journal-title":"Cancer"},{"issue":"1","key":"2685_CR166","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12885-021-07782-z","volume":"21","author":"J Fraisse","year":"2021","unstructured":"Fraisse J, Dinart D, Tosi D, Bellera C, Mollevi C. Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer. 2021;21(1):60.","journal-title":"BMC Cancer"},{"key":"2685_CR167","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1182\/blood-2022-157729","volume":"140","author":"EL Budde","year":"2022","unstructured":"Budde EL, Bartlett NL, Giri P, Schuster SJ, Assouline S, Yoon SS, et al. Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed\/Refractory (R\/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I\/II Study. Blood. 2022;140:3753\u20135.","journal-title":"Blood"},{"issue":"2","key":"2685_CR168","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2685_CR169","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146(5):940\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"2685_CR170","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cytogfr.2016.05.002","volume":"31","author":"J Banuelos","year":"2016","unstructured":"Banuelos J, Lu NZ. A gradient of glucocorticoid sensitivity among helper T cell cytokines. Cytokine Growth F R. 2016;31:27\u201335.","journal-title":"Cytokine Growth F R"},{"issue":"4","key":"2685_CR171","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of Immunotherapy-Related Toxicities, Version 1.2022. J Natl Compr Canc Ne. 2022;20(4):387\u2013405.","journal-title":"J Natl Compr Canc Ne"},{"issue":"20","key":"2685_CR172","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430\u201342.","journal-title":"Blood"},{"key":"2685_CR173","doi-asserted-by":"crossref","unstructured":"Ferreros P, Trapero I. Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy. Diseases. 2022;10(3):41.","DOI":"10.3390\/diseases10030041"},{"issue":"6","key":"2685_CR174","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00277-025-06467-y","volume":"104","author":"X Wang","year":"2025","unstructured":"Wang X, He X, Zhang T, Liu J, Zhao M. Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies. Ann Hematol. 2025;104(6):3129\u201351.","journal-title":"Ann Hematol"},{"key":"2685_CR175","doi-asserted-by":"publisher","first-page":"766275","DOI":"10.3389\/fimmu.2021.766275","volume":"12","author":"SJC Mancini","year":"2021","unstructured":"Mancini SJC, Balabanian K, Corre I, Gavard J, Lazennec G, Le Bousse-Kerdiles MC, et al. Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. Front Immunol. 2021;12:766275.","journal-title":"Front Immunol"},{"issue":"1","key":"2685_CR176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):1\u201312.","journal-title":"Cell Mol Immunol"},{"key":"2685_CR177","doi-asserted-by":"publisher","first-page":"1425136","DOI":"10.3389\/fimmu.2024.1425136","volume":"15","author":"M Ganjalikhani-Hakemi","year":"2024","unstructured":"Ganjalikhani-Hakemi M, Yanikkaya Demirel G, He X, Zeng C, Editorial. Immunologic tumor microenvironment modulators for turning cold tumors to hot tumors. Front Immunol. 2024;15:1425136.","journal-title":"Front Immunol"},{"issue":"7","key":"2685_CR178","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","volume":"6","author":"QQ Duan","year":"2020","unstructured":"Duan QQ, Zhang HL, Zheng JN, Zhang LJ. Turning Cold into Hot: Firing up the Tumor Microenvironment. Trends Cancer. 2020;6(7):605\u201318.","journal-title":"Trends Cancer"},{"key":"2685_CR179","doi-asserted-by":"crossref","unstructured":"Groeneveldt C, Kinderman P, van den Wollenberg DJM, van den Oever RL, Middelburg J, Mustafa DAM et al. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy. J Immunother Cancer. 2020;8(2):e001191.","DOI":"10.1136\/jitc-2020-001191"},{"key":"2685_CR180","doi-asserted-by":"crossref","unstructured":"Smestad J, Rieth J, Laux D, Milhem M. The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. Cells. 2025;14(20):1620.","DOI":"10.3390\/cells14201620"},{"issue":"2","key":"2685_CR181","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"2685_CR182","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.21037\/atm-21-1948","volume":"9","author":"L Zhu","year":"2021","unstructured":"Zhu L, Jiang M, Wang H, Sun H, Zhu J, Zhao W, et al. A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med. 2021;9(16):1351.","journal-title":"Ann Transl Med"},{"issue":"5","key":"2685_CR183","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41375-018-0014-3","volume":"32","author":"CE Correnti","year":"2018","unstructured":"Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia. 2018;32(5):1239\u201343.","journal-title":"Leukemia"},{"issue":"8","key":"2685_CR184","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","volume":"10","author":"J Yun","year":"2020","unstructured":"Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020;10(8):1194\u2013209.","journal-title":"Cancer Discov"},{"issue":"30","key":"2685_CR185","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021;39(30):3391\u2013402.","journal-title":"J Clin Oncol"},{"key":"2685_CR186","doi-asserted-by":"publisher","first-page":"1665838","DOI":"10.3389\/fimmu.2025.1665838","volume":"16","author":"A Spinazzola","year":"2025","unstructured":"Spinazzola A, Iannantuono GM, Gulley JL, Giudice E, Filetti M, Sganga S, et al. Current landscape of T-cell engagers in early-phase clinical development in solid cancers. Front Immunol. 2025;16:1665838.","journal-title":"Front Immunol"},{"key":"2685_CR187","doi-asserted-by":"crossref","unstructured":"Sun Y, Zhou L, Gu X. Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer (13, e010140, 2025). J Immunother Cancer. 2025;13(3):e010140.","DOI":"10.1136\/jitc-2024-010140"},{"key":"2685_CR188","doi-asserted-by":"crossref","unstructured":"Pillarisetti R, Yang DL, Yao JH, Smith M, Luistro L, Vulfson P et al. Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma. Blood. 2023;142 (Supplement 1):456.","DOI":"10.1182\/blood-2023-174941"},{"issue":"5","key":"2685_CR189","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/bjh.70116","volume":"207","author":"XT Wang","year":"2025","unstructured":"Wang XT, Cui YS, Wang YM, Fang BJ. Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies. Brit J Haematol. 2025;207(5):1765\u201378.","journal-title":"Brit J Haematol"},{"issue":"3","key":"2685_CR190","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2326-6066.CIR-18-0622","volume":"7","author":"D Neri","year":"2019","unstructured":"Neri D. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity. Cancer Immunol Res. 2019;7(3):348\u201354.","journal-title":"Cancer Immunol Res"},{"key":"2685_CR191","doi-asserted-by":"crossref","unstructured":"Abbas AK, Trotta E, Marson DRS, Bluestone A. JA. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. 2018;3(25):eaat1482.","DOI":"10.1126\/sciimmunol.aat1482"},{"issue":"1","key":"2685_CR192","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0092-8674(93)90152-G","volume":"73","author":"T Taniguchi","year":"1993","unstructured":"Taniguchi T, Minami Y. The IL-2\/IL-2 receptor system: a current overview. Cell. 1993;73(1):5\u20138.","journal-title":"Cell"},{"key":"2685_CR193","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/j.clim.2020.108515","volume":"218","author":"J Damoiseaux","year":"2020","unstructured":"Damoiseaux J. The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. Clin Immunol. 2020;218:108515.","journal-title":"Clin Immunol"},{"issue":"1","key":"2685_CR194","doi-asserted-by":"publisher","first-page":"2381891","DOI":"10.1080\/19420862.2024.2381891","volume":"16","author":"P Murer","year":"2024","unstructured":"Murer P, Brannetti B, Rondeau JM, Petersen L, Egli N, Popp S, et al. Discovery and development of ANV419, an IL-2\/anti-IL-2 antibody fusion protein with potent CD8\u2009+\u2009T and natural killer cell-stimulating capacity for cancer immunotherapy. MAbs. 2024;16(1):2381891.","journal-title":"MAbs"},{"key":"2685_CR195","doi-asserted-by":"crossref","unstructured":"Joerger M, Calvo E, Laubli H, Lopez J, Alonso G, de la Fuente EC et al. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed\/refractory advanced solid tumors. J Immunother Cancer. 2023;11(11):e007784.","DOI":"10.1136\/jitc-2023-007784"},{"issue":"9","key":"2685_CR196","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","volume":"4","author":"WW Wu","year":"2023","unstructured":"Wu WW, Chia TS, Lu J, Li X, Guan J, Li YN, et al. IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25 CD8 T cells. Nat Cancer. 2023;4(9):1309\u2013.","journal-title":"Nat Cancer"},{"key":"2685_CR197","first-page":"16","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen Y, Lin J, Wang H, Zhang WZ, Liang XJ, Cui JW, et al. First-in-class PD-1\/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study. J Clin Oncol. 2024;42:16.","journal-title":"J Clin Oncol"},{"key":"2685_CR198","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3389\/fimmu.2017.01804","volume":"8","author":"I Corraliza-Gorjon","year":"2017","unstructured":"Corraliza-Gorjon I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L. New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Front Immunol. 2017;8:1804.","journal-title":"Front Immunol"},{"key":"2685_CR199","doi-asserted-by":"crossref","unstructured":"Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y. Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody. Where Are We Now? Biomedicines. 2022;10(9):2113.","DOI":"10.3390\/biomedicines10092113"},{"key":"2685_CR200","doi-asserted-by":"publisher","first-page":"1568724","DOI":"10.3389\/fimmu.2025.1568724","volume":"16","author":"Y Yan","year":"2025","unstructured":"Yan Y, Yuan J, Peng Y, Zhou C, Liu X, Sun L, et al. Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward? Front Immunol. 2025;16:1568724.","journal-title":"Front Immunol"},{"issue":"7","key":"2685_CR201","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.7150\/ijbs.125834","volume":"22","author":"S Yang","year":"2026","unstructured":"Yang S, Zhang Z, He X, Ouyang Z, Tang S, Liang M, et al. Luteolin enhances antitumor immunity of B7-H3-targeted bispecific natural killer cell engagers against non-small cell lung cancer. Int J Biol Sci. 2026;22(7):3731\u201348.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"2685_CR202","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10549-025-07676-9","volume":"211","author":"C Zhang","year":"2025","unstructured":"Zhang C, Liu J, Gu T, Meng X, Cai X, Zhang J, et al. Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation. Breast Cancer Res Treat. 2025;211(3):637\u201348.","journal-title":"Breast Cancer Res Treat"},{"key":"2685_CR203","doi-asserted-by":"crossref","unstructured":"Mueller T, Freystein J, Lucas H, Schmoll HJ. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. Molecules. 2019;24(16):2865.","DOI":"10.3390\/molecules24162865"},{"key":"2685_CR204","doi-asserted-by":"crossref","unstructured":"Sano Y, Azuma Y, Tsunenari T, Kayukawa Y, Shinozuka J, Fujii E et al. Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours. Nat Commun. 2022;13(1):5265.","DOI":"10.1038\/s41467-022-32952-3"},{"key":"2685_CR205","doi-asserted-by":"crossref","unstructured":"Zhao YY, Chen G, Chen JH, Zhuang L, Du YY, Yu QT et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. Eclinicalmedicine. 2023;62:102106.","DOI":"10.1016\/j.eclinm.2023.102106"},{"key":"2685_CR206","doi-asserted-by":"crossref","unstructured":"Jang JY, Kim D, Kim ND. Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors. Int J Mol Sci. 2023;24(9):8457.","DOI":"10.3390\/ijms24098457"},{"key":"2685_CR207","doi-asserted-by":"crossref","unstructured":"Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol. 2022;12:960317.","DOI":"10.3389\/fonc.2022.960317"},{"issue":"1","key":"2685_CR208","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","volume":"24","author":"B Chen","year":"2025","unstructured":"Chen B, Zheng X, Wu J, Chen G, Yu J, Xu Y, et al. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer. 2025;24(1):279.","journal-title":"Mol Cancer"},{"issue":"3","key":"2685_CR209","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"2685_CR210","doi-asserted-by":"crossref","unstructured":"Theocharopoulos C, Lialios PP, Samarkos M, Gogas H, Ziogas DC. Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. Vaccines-Basel. 2021;9(10):1111.","DOI":"10.3390\/vaccines9101111"},{"key":"2685_CR211","doi-asserted-by":"crossref","unstructured":"Liu KF, Li MJ, Li YD, Li YT, Chen ZX, Tang YQ et al. A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers. Mol Cancer. 2024;23(1):62.","DOI":"10.1186\/s12943-024-01963-7"},{"key":"2685_CR212","doi-asserted-by":"crossref","unstructured":"Chia CSB. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads. ChemMedChem. 2022;17(11):e202200032.","DOI":"10.1002\/cmdc.202200032"},{"key":"2685_CR213","doi-asserted-by":"crossref","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R et al. Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci. 2023;24(11):9674.","DOI":"10.3390\/ijms24119674"},{"issue":"2","key":"2685_CR214","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2024024442","volume":"144","author":"RP Taylor","year":"2024","unstructured":"Taylor RP, Lindorfer MA. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms. Blood. 2024;144(2):137\u201344.","journal-title":"Blood"},{"issue":"1","key":"2685_CR215","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12272-026-01595-z","volume":"49","author":"Y Bai","year":"2026","unstructured":"Bai Y, Lei H, Gou S, Lan J, Cai D, Zheng X, et al. Bispecific antibody-drug conjugates: a modular blueprint for next-generation cancer therapeutics. Arch Pharm Res. 2026;49(1):61\u2013100.","journal-title":"Arch Pharm Res"},{"issue":"2","key":"2685_CR216","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10637-025-01507-w","volume":"43","author":"H Huang","year":"2025","unstructured":"Huang H, Zhou Y, Shang C, Zhang Y, Shen Y. A novel anti-HER2\/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs. Invest New Drugs. 2025;43(2):262\u201375.","journal-title":"Invest New Drugs"},{"issue":"11","key":"2685_CR217","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1535-7163.MCT-24-0078","volume":"23","author":"HT Yue","year":"2024","unstructured":"Yue HT, Xu H, Ma LP, Li XY, Yang BY, Wang XY, et al. A DXd\/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation. Mol Cancer Ther. 2024;23(11):1639\u201351.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2685_CR218","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1158\/1535-7163.MCT-16-0364","volume":"15","author":"BE de Goeij","year":"2016","unstructured":"de Goeij BE, Vink T, Ten Napel H, Breij EC, Satijn D, Wubbolts R, et al. Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63. Mol Cancer Ther. 2016;15(11):2688\u201397.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"2685_CR219","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1038\/s41591-025-03792-7","volume":"31","author":"C Liu","year":"2025","unstructured":"Liu C, Liu D, Ji Y, Sun M, Gao S, Ma X, et al. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2025;31(10):3485\u201391.","journal-title":"Nat Med"},{"key":"2685_CR220","doi-asserted-by":"crossref","unstructured":"Zhang XG, Jin YP, Lu JC, Li NH, Wu ZH, Wu M, et al. IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models. Cancer Res. 2025;85(8).","DOI":"10.1158\/1538-7445.AM2025-344"},{"key":"2685_CR221","unstructured":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors. https:\/\/clinicaltrials.gov\/study\/NCT06974812?term=%22solid%20tumors%22&aggFilters=studyType:int. Accessed 31 March 2026."},{"key":"2685_CR222","doi-asserted-by":"crossref","unstructured":"Dewaker V, Morya VK, Kim YH, Park ST, Kim HS, Koh YH. Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools. Biomark Res. 2025;13(1):52.","DOI":"10.1186\/s40364-025-00764-4"},{"key":"2685_CR223","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2023.06.005","volume":"95","author":"GG Bai","year":"2023","unstructured":"Bai GG, Sun CC, Guo Z, Wang YJ, Zeng XC, Su YH, et al. Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects. Semin Cancer Biol. 2023;95:13\u201324.","journal-title":"Semin Cancer Biol"},{"key":"2685_CR224","doi-asserted-by":"crossref","unstructured":"Krokidis MG, Koumadorakis DE, Lazaros K, Ivantsik O, Exarchos TP, Vrahatis AG et al. AlphaFold3: An Overview of Applications and Performance Insights. Int J Mol Sci. 2025;26(8):3671.","DOI":"10.3390\/ijms26083671"},{"key":"2685_CR225","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/bioinformatics\/btaa457","volume":"36","author":"JA Ruffolo","year":"2020","unstructured":"Ruffolo JA, Guerra C, Mahajan SP, Sulam J, Gray JJ. Geometric potentials from deep learning improve prediction of CDR H3 loop structures. Bioinformatics. 2020;36:268\u201375.","journal-title":"Bioinformatics"},{"key":"2685_CR226","doi-asserted-by":"crossref","unstructured":"Ruffolo JA, Sulam J, Gray JJ. Antibody structure prediction using interpretable deep learning. Patterns. 2022;3(2):100406.","DOI":"10.1016\/j.patter.2021.100406"},{"issue":"7","key":"2685_CR227","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/bioinformatics\/btac016","volume":"38","author":"B Abanades","year":"2022","unstructured":"Abanades B, Georges G, Bujotzek A, Deane CM. ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation. Bioinformatics. 2022;38(7):1877\u201380.","journal-title":"Bioinformatics"},{"issue":"1","key":"2685_CR228","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41421-025-00843-8","volume":"11","author":"Y Kong","year":"2025","unstructured":"Kong Y, Shi J, Wu F, Zhao T, Wang R, Zhu X, et al. A synergistic generative-ranking framework for tailored design of therapeutic single-domain antibodies. Cell Discov. 2025;11(1):85.","journal-title":"Cell Discov"},{"issue":"7989","key":"2685_CR229","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41586-023-06728-8","volume":"623","author":"JB Ingraham","year":"2023","unstructured":"Ingraham JB, Baranov M, Costello Z, Barber KW, Wang W, Ismail A, et al. Illuminating protein space with a programmable generative model. Nature. 2023;623(7989):1070\u20138.","journal-title":"Nature"},{"key":"2685_CR230","doi-asserted-by":"publisher","first-page":"7849108","DOI":"10.1155\/2017\/7849108","volume":"2017","author":"M Di Modica","year":"2017","unstructured":"Di Modica M, Tagliabue E, Triulzi T. Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. Dis Markers. 2017;2017:7849108.","journal-title":"Dis Markers"},{"issue":"Suppl 1","key":"2685_CR231","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/annonc\/12.suppl_1.S49","volume":"12","author":"J Baselga","year":"2001","unstructured":"Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol. 2001;12(Suppl 1):S49\u201355.","journal-title":"Ann Oncol"},{"issue":"14","key":"2685_CR232","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2011.37.4207","volume":"30","author":"J Cortes","year":"2012","unstructured":"Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(14):1594\u2013600.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2685_CR233","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1053\/j.seminhematol.2025.08.004","volume":"62","author":"H Lee","year":"2025","unstructured":"Lee H, Lee Y, Chung J. Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers. Semin Hematol. 2025;62(4):279\u201388.","journal-title":"Semin Hematol"},{"issue":"1","key":"2685_CR234","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-024-01956-6","volume":"23","author":"L Cheng","year":"2024","unstructured":"Cheng L, Chen L, Shi Y, Gu W, Ding W, Zheng X, et al. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison. Mol Cancer. 2024;23(1):77.","journal-title":"Mol Cancer"},{"issue":"5","key":"2685_CR235","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","volume":"11","author":"SJ Dovedi","year":"2021","unstructured":"Dovedi SJ, Elder MJ, Yang CN, Sitnikova S, Irving L, Hansen A, et al. Design and Efficacy of a Monovalent Bispecific PD-1\/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 Activated T Cells. Cancer Discov. 2021;11(5):1100\u201317.","journal-title":"Cancer Discov"},{"issue":"13","key":"2685_CR236","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13):1270\u20131.","journal-title":"N Engl J Med"},{"issue":"21","key":"2685_CR237","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"11","key":"2685_CR238","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1038\/s41591-025-03967-2","volume":"31","author":"GV Long","year":"2025","unstructured":"Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, et al. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b\/2 Morpheus-Melanoma trial. Nat Med. 2025;31(11):3700\u201312.","journal-title":"Nat Med"},{"issue":"3","key":"2685_CR239","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.7150\/thno.81494","volume":"13","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, Compte M, Alvarez-Vallina L, Sanz L. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics. 2023;13(3):1028\u201341.","journal-title":"Theranostics"},{"issue":"4","key":"2685_CR240","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/imm.13636","volume":"169","author":"Y Yao","year":"2023","unstructured":"Yao Y, Hu Y, Wang F. Trispecific antibodies for cancer immunotherapy. Immunology. 2023;169(4):389\u201399.","journal-title":"Immunology"},{"key":"2685_CR241","doi-asserted-by":"publisher","first-page":"102937","DOI":"10.1016\/j.ctrv.2025.102937","volume":"136","author":"WY Kong","year":"2025","unstructured":"Kong WY, Soderholm A, Brooks AJ, Gonzalez Cruz JL, Wells JW. Harnessing cytokine immunocomplexes and cytokine fusion proteins for cancer Therapy: Mechanisms and clinical potential. Cancer Treat Rev. 2025;136:102937.","journal-title":"Cancer Treat Rev"},{"key":"2685_CR242","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.biochi.2020.08.019","volume":"177","author":"H Ma","year":"2020","unstructured":"Ma H, O\u2019Fagain C, O\u2019Kennedy R. Antibody stability: A key to performance - Analysis, influences and improvement. Biochimie. 2020;177:213\u201325.","journal-title":"Biochimie"},{"issue":"1","key":"2685_CR243","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12935-025-03869-w","volume":"25","author":"A Dozandeh-Jouybari","year":"2025","unstructured":"Dozandeh-Jouybari A, Rohaninia E, Faaliat S, Joudaki N, Ghandi S, Moghaddam MT, et al. One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors. Cancer Cell Int. 2025;25(1):254.","journal-title":"Cancer Cell Int"},{"key":"2685_CR244","doi-asserted-by":"crossref","unstructured":"Khan SR, Breadner D. Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment. Curr Oncol. 2025;32(4):206.","DOI":"10.3390\/curroncol32040206"},{"issue":"8","key":"2685_CR245","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/00498254.2024.2352051","volume":"54","author":"ME Gray","year":"2024","unstructured":"Gray ME, Zielinski KM, Xu F, Elder KK, McKay SJ, Ojo VT, et al. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers. Xenobiotica. 2024;54(8):458\u201368.","journal-title":"Xenobiotica"},{"issue":"12","key":"2685_CR246","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B. 2021;11(12):3889\u2013907.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"2685_CR247","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11095-023-03649-z","volume":"41","author":"M Li","year":"2024","unstructured":"Li M, Zhao X, Yu C, Wang L. Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy. Pharm Res. 2024;41(3):419\u201340.","journal-title":"Pharm Res"},{"issue":"4","key":"2685_CR248","first-page":"728","volume":"34","author":"T Fujii","year":"2023","unstructured":"Fujii T, Matsuda Y, Seki T, Shikida N, Iwai Y, Ooba Y, et al. AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production. Bioconjug Chem. 2023;34(4):728\u201338.","journal-title":"Bioconjug Chem"},{"issue":"1\u20132","key":"2685_CR249","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14712598.2024.2305266","volume":"24","author":"DV Hingorani","year":"2024","unstructured":"Hingorani DV. An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio. Expert Opin Biol Ther. 2024;24(1\u20132):31\u20136.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"2685_CR250","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s41061-025-00497-w","volume":"383","author":"J Zhang","year":"2025","unstructured":"Zhang J, Yang Z, Liu Y, Liu Y, Qu J, Pan X. Recent Advances in Smart Linkage Strategies for Developing Drug Conjugates for Targeted Delivery. Top Curr Chem (Cham). 2025;383(2):13.","journal-title":"Top Curr Chem (Cham)"},{"key":"2685_CR251","doi-asserted-by":"publisher","first-page":"102902","DOI":"10.1016\/j.ctrv.2025.102902","volume":"134","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Saw SPL, Hendriks L, Menis J, Cascone T, Arrieta O, et al. Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target. Cancer Treat Rev. 2025;134:102902.","journal-title":"Cancer Treat Rev"},{"key":"2685_CR252","doi-asserted-by":"crossref","unstructured":"Xie D, Yang C, Gao S, Li J, Yang J, Li X et al. Antibody-Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives. Int J Mol Sci. 2026;27(7):3287.","DOI":"10.3390\/ijms27073287"},{"key":"2685_CR253","doi-asserted-by":"crossref","unstructured":"Buyukgolcigezli I, Tenekeci AK, Sahin IH. Opportunities and Challenges in Antibody-Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment. Cancers (Basel). 2025;17(6):958.","DOI":"10.3390\/cancers17060958"},{"issue":"8","key":"2685_CR254","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s43588-025-00823-8","volume":"5","author":"AM Hummer","year":"2025","unstructured":"Hummer AM, Schneider C, Chinery L, Deane CM. Investigating the volume and diversity of data needed for generalizable antibody-antigen DeltaDeltaG prediction. Nat Comput Sci. 2025;5(8):635\u201347.","journal-title":"Nat Comput Sci"},{"issue":"1","key":"2685_CR255","doi-asserted-by":"publisher","first-page":"2570962","DOI":"10.1080\/21645515.2025.2570962","volume":"21","author":"J Zumarraga","year":"2025","unstructured":"Zumarraga J, McConnell MJ, Lopez D, Martin-Galiano AJ. Legal questions of AI-generated immunological products for infectious diseases. Hum Vaccin Immunother. 2025;21(1):2570962.","journal-title":"Hum Vaccin Immunother"},{"key":"2685_CR256","doi-asserted-by":"crossref","unstructured":"Chungyoun M, Gray J. Fitness Landscape for Antibodies 2: Benchmarking Reveals That Protein AI Models Cannot Yet Consistently Predict Developability Properties. bioRxiv. 2025.","DOI":"10.64898\/2025.12.27.696706"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02685-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02685-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02685-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:03:30Z","timestamp":1785895410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02685-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":256,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2685"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02685-8","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"189"}}